GOTHENBURG, Sweden — September 8, 2026
Epicyt Pharma AB reported positive topline results from its Phase 1/2a first-in-human study of BAFA in patients who underwent Roux-en-Y gastric bypass (RYGB) surgery, providing a clinical development milestone for the company’s lead program targeting impaired intestinal calcium uptake. The study demonstrated a statistically significant reduction in urinary calcium excretion, together with improvements in key biomarkers associated with calcium homeostasis. Epicyt said the findings are consistent with an improvement in intestinal calcium uptake and support the company’s plans to advance BAFA into Phase 2b development. The study, which was completed in March 2026, represents an important proof-of-concept step for the Gothenburg-based clinical-stage biopharmaceutical company as it develops what it describes as a first-in-class oral approach to improving calcium balance following bariatric surgery. The program is focused on a population where impaired calcium absorption remains a significant clinical challenge despite standard supplementation with calcium and vitamin D..
BAFA Targets Post-Surgical Calcium Imbalance
BAFA is an oral drug candidate combining a bile acid and a short-chain fatty acid to enhance intestinal calcium uptake, offering a different therapeutic approach from conventional post-bypass supplementation. RYGB is widely used for the treatment of severe obesity but can impair the body’s ability to absorb calcium, potentially contributing to secondary hyperparathyroidism, reduced bone density, and increased fracture risk. Epicyt’s Phase 1/2a findings indicate that BAFA produced coordinated biological changes in markers of calcium homeostasis, including the statistically significant reduction in urinary calcium excretion. Principal Investigator Dr. Ville Wallenius said the short proof-of-concept study was designed to demonstrate an immediate calcium-balance effect and that the observed biological effects support further development. For Epicyt, the results provide early clinical validation of its strategy to directly improve intestinal calcium handling rather than relying solely on calcium and vitamin D supplementation.
Phase 2b Program Planned Following Proof of Concept
Epicyt is preparing to move BAFA into Phase 2b development, making the next clinical stage the company’s key near-term development milestone. The Phase 1/2a study provides initial human evidence for BAFA’s biological activity, while a larger Phase 2b program is expected to further evaluate the candidate’s potential in patients experiencing impaired calcium homeostasis after gastric bypass surgery. The company’s development strategy addresses a substantial patient population, with Epicyt estimating that approximately 3.5 million people in the European Union and United States live with impaired calcium homeostasis following gastric surgery for obesity, with approximately 250,000 new patients added annually. These figures underline the potential commercial opportunity for a therapy specifically designed to address post-bariatric calcium absorption. Epicyt’s worldwide rights to BAFA provide the company with control over further development and potential commercialization of the program as it progresses toward later-stage clinical evaluation.
Epicyt Builds Differentiated Metabolic Bone Disease Pipeline
The BAFA program positions Epicyt Pharma around an overlooked mechanism contributing to metabolic bone disease following bariatric surgery, with the company seeking to establish a new treatment category focused on intestinal calcium uptake. Current post-bypass management commonly relies on calcium and vitamin D supplementation, but persistent impairment of calcium absorption can leave patients with ongoing risks related to calcium imbalance and skeletal health. The positive Phase 1/2a topline findings give Epicyt a foundation for continued clinical development and regulatory planning as the company prepares its Phase 2b program. By combining its clinical-stage status with worldwide rights to a first-in-class oral candidate, Epicyt is advancing BAFA toward a potentially differentiated treatment option for patients affected by post-surgical calcium malabsorption. The transition into Phase 2b will now be closely watched as the company seeks to build on the initial biological evidence and establish a stronger clinical development package for BAFA.
Source:Epicyt Pharma press release



